Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now full pipeline small index

ESRD: full-pipeline trial registry

5 of 14 indexed ESRD trials are currently recruiting.

Corpus placement: #1,230 of 28,707 conditions by registered trial count.

14 US clinical trials · 5 currently recruiting · #1,230 of 28,707 conditions by registered trial count

ESRD: 14 US clinical trials tracked, 5 recruiting.

ESRD is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Fresenius Medical Care North America, running 2 of these trials.

Enrollment posture brief

Registry condition esrd

OPEN 5 | RECR 36% | LATE 3 | EARLY 2 | RANK #1230 | SPON 2

Nearest open-share peer: Attention (36% recruiting · 14 trials)

ESRD (this)36%Acute Respiratory Failure35.7%Adherence, Medication35.7%Acromegaly28.6%Abscess7.1%
Open-enrollment share among volume-matched conditions near ESRD

ESRD lists 5 open slots (36% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for ESRD on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. ESRD is recruiting below its size-band peers.

    5 of 14 indexed trials (35.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of ESRD trials is spread across many organizations.

    Fresenius Medical Care North America accounts for 2 of 14 trials (14.3%). 12 distinct sponsors appear on at least one study for this condition label.

  3. Typical ESRD enrolment sits around 100 participants.

    Median target enrolment is 100 among the 14 trials that report a genuine target (sentinel values excluded). 7 of those (50%) plan for fewer than 100 participants.

  4. ESRD research is mostly interventional.

    13 interventional and 1 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 32Phase 41

Open and recent trials

14 total, page 1 of 1

RECRUITING NA 600 participants

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

VenoStent

NCT06001827

RECRUITING NA 100 participants

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

Hennepin Healthcare Research Institute

NCT05879302

RECRUITING NA 100 participants

Repletion of Ergothioneine in Patients With Kidney Failure

Stanford University

NCT06487546

RECRUITING Phase 3 50 participants

SAfety of Regional Citrate Anticoagulation (SARCA Study)

Fresenius Medical Care North America

NCT05339139

RECRUITING Phase 1 20 participants

Adding Urea to the Final Dialysis Fluid

University of California, San Francisco

NCT06366230

COMPLETED Phase 3 269 participants

Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

Vascular Therapies

NCT02513303

COMPLETED 175 participants

StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation

Nova Biomedical

NCT05144971

COMPLETED NA 142 participants

Reducing Chronic Kidney Disease Burden in an Underserved Population

Baylor Research Institute

NCT03832166

COMPLETED NA 131 participants

Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis

Stanford University

NCT03327909

COMPLETED Phase 2 88 participants

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

Ardelyx

NCT01764854

COMPLETED Phase 4 81 participants

Phosphate Kinetic Modeling 2

Fresenius Medical Care North America

NCT01252771

COMPLETED NA 42 participants

Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT

University of Pennsylvania

NCT02778516

COMPLETED NA 30 participants

Comparison of Different Glucose Concentrations in Dialysate of Hemodialysis Patients

Renal Research Institute

NCT00618033

COMPLETED NA 2 participants

Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR

University of Florida

NCT02669966

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on ESRD records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sirolimus-eluting Collagen Implant (SeCI) Device
1 trials
AV Fistula Surgery Procedure
1 trials
Fruits and Vegetables Other
1 trials
TAKE vs. HOLD Behavioral
1 trials
PKM Algorithm Other
1 trials
Glucose, Creatinine Diagnostic test
1 trials
AZD1722 (out-patient) Drug
1 trials
Placebo (in-patient) Drug
1 trials

US sites by state

Facility locations filed on ESRD trials. A trial with sites in several states counts in each.

California 5 trials
Minnesota 4 trials
Florida 4 trials
New York 3 trials
Arizona 3 trials
Pennsylvania 2 trials
Missouri 2 trials
Massachusetts 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this ESRD page

14 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ESRD condition card totals 14 registered trials; most-linked intervention Sirolimus-eluting Collagen Implant (SeCI); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.